News & Event Videos

Researchers who analyzed emerging hypotheses for the pathogenesis of GBA1 variants and reviewed recent studies say their findings add to existing evidence that Parkinson's disease is not a single condition but rather a collection of disorders with various underlying causes. Better understanding of these genetic factors could help bring the field closer to more precise, personalized diagnoses and treatments.

Dr. Stephen Strittmatter and a Yale-led team secured a major three-year research grant to investigate molecular mechanisms of Parkinson's disease. This initiative is part of a broader $261 million international effort backed by the Aligning Science Across Parkinson’s program and the Michael J. Fox Foundation.

Molecules found on the surface of motor neurons in the brain help traffic a misfolded protein into cells, leading to the motor symptoms of Parkinson’s disease.

Our new research center at Yale has surged forward on multiple fronts: new drug discovery via AI, powerful biomarker studies, and a thriving clinical program.

New findings reveal motor and cognitive deficits arise through separate mechanisms in Parkinson’s disease, challenging previous thinking.

The Yale Legacy Tissue donation program has provided over 1,500 tissue samples to Yale researchers since its creation in 2022.

A Yale study finds specialized immune cells in the brains of mice and humans in the absence of disease, questioning previous dogma about interactions between the brain and the immune system.

A new study on a gene called VPS13C adds to growing evidence that lysosomal dysfunction may be one mechanism through which Parkinson’s disease arises.

Longevity experts see fighting chronic inflammation as key to healthier aging. Dr. David Hafler discusses inflammation as a "double-edge sword."